Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
Nia JulianJuly 27, 2021
Facebook0 Twitter Pinterest0 0 Likes
Previous

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline

Nia JulianAugust 18, 2021
Next

Rallybio hits high gear as it targets $100M IPO to fund treatments for rare fetal bleeding disorder

Nia JulianJuly 12, 2021

© 2020 Solasta Ventures. All Rights Reserved.